Chemotalk Newsletter

The Chemotalk Newsletter is published once a month, and contains an overview of news stories that relate to chemotherapy treatment for cancer, multiple sclerosis, rheumatoid arthritis, or for anyone who has received an organ transplant.

Sign up to receive the monthly
Chemotalk Newsletter, and bulletins
about important chemotherapy breakthroughs.
E-mail address:
Subscribe Unsubscribe
 
Chemotalk Newsletter, Vol. 114: October 1, 2017

Much happening, treatment-wise, beginning with...

NIVOLUMAB NEW STANDARD FOR ADVANCED, HIGH-RISK RESECTED MELANOMA

By Leah Lawrence

Nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with stage III/IV MELANOMA at high risk for recurrence, according to results of the CheckMate 238 study (abstract LBA8_PR) presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid. Ipilimumab is currently the US Food and Drug Administration (FDA)-approved standard of care treatment for resected stage III melanoma in the United States.

"The results clearly show that relapse-free survival is more favorable with Nivolumab," investigator Jeffrey Weber, MD, deputy director, Perlmutter Cancer Center, NYU Langone Health, said in a press release. "The majority of patients had higher risk disease than in most prior adjuvant melanoma trials, which makes the findings even more encouraging."

The study included 906 patients aged 15 or older with complete resection of stage IIIb (34%), stage IIIc (47%), or stage IV (19%) melanoma. They were randomly assigned to Nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses, then every 12 weeks for up to 1 year.

The trial was stopped early after clear evidence of a benefit with Nivolumab. At a follow-up of 18.5 months, treatment with Nivolumab resulted in a 35% lower risk for recurrence compared with ipilimumab (hazard ratio, 0.65; 95% CI, 0.51­0.83). The 18-month recurrence-free survival was 66.4% compared with 52.7% for ipilimumab (P < .0001).

There were similar results across prespecified subgroups of patients including analyses of PD-L1 expression, which showed hazard ratios in favor of Nivolumab.

"A previous trial found that ipilimumab had a significant relapse-free and overall survival advantage compared to placebo," Weber said. "CheckMate
238 shows that Nivolumab is superior to ipilimumab, so extrapolating these results, Nivolumab is far better than no adjuvant treatment for high-risk melanoma. It is also much less toxic than ipilimumab.

Read more...

Vol 105: January, 2017

Vol 106: February, 2017

Vol 109: May, 2017

Vol 110: June, 2017

Vol 111: July, 2017

Vol 112: August, 2017

Vol 113: September, 2017

Vol 114: October, 2017

Vol 93: January, 2016

Vol. 94: February, 2016

Vol. 95: March, 2016

Vol. 96: April, 2016

Vol. 97: May, 2016

Vol. 98: June, 2016

Vol. 99: July, 2016

Vol. 100: August, 2016

Vol. 101: September, 2016

Vol. 102: October, 2016

Vol. 103: November, 2016

Vol. 104: December, 2016

Vol 81: January, 2015

Vol 82: February, 2015

Vol 83: March, 2015

Vol 84: April, 2015

Vol 85: May, 2015

Vol 86: June, 2015

Vol 87: July, 2015

Vol 88: August, 2015

Vol 89: September, 2015

Vol 90: October, 2015

Vol 91: November, 2015

Vol 92: December, 2015

Vol. 69: January, 2014

Vol 70: February, 2014

Vol 71: March, 2014

Vol 72: April, 2014

Vol 73: May, 2014

Vol 74: June, 2014

Vol 75: July, 2014

Vol 76: August, 2014

Vol 77: September, 2014

Vol 78: October, 2014

Vol 79: November, 2014

Vol 80: December, 2014

Vol 57: January, 2013

Vol 58: February, 2013

Vol 59: March, 2013

Vol. 60: April, 2013

Vol. 61: May, 2013

Vol. 62: June, 2013

Vol. 63: July, 2013

Vol. 64: August, 2013

Vol. 65: September, 2013

Vol. 66: October, 2013

Vol. 67: November, 2013

Vol. 68: December, 2013

Vol 56: December, 2012

Vol 55: November, 2012

Vol 54: October, 2012

Vol 53: September, 2012

Vol 52: August, 2012

Vol 51: July, 2012

Vol 50: June, 2012

Vol 49: May, 2012

Vol 48: April, 2012

Vol 47: March, 2012

Vol 46: February, 2012

Vol 45: January, 2012

Vol 44: December, 2011

Vol 43: November, 2011

Vol 42: October, 2011

Vol 41: September, 2011

Vol 40: August, 2011

Vol 39: July, 2011

Vol 38: June, 2011

Vol 37: May 1, 2011

Vol 36: April 1, 2011

Vol 35: March 1, 2011

Vol 34: February 1, 2011

Vol 33: January 1, 2011

Vol 32: December 1, 2010

Vol 31: November 1, 2010

Vol 30: October 1, 2010

Vol 29: September, 2010

Vol 28: August, 2010

Vol 27: July, 2010

Vol 26: June, 2010

Vol. 25: May, 2010

Vol. 24: April, 2010

Vol. 23: March, 2010

Vol. 22: February, 2010

Vol. 21: January, 2010

Vol. 20: December, 2009

Vol. 19: November, 2009

Vol. 18: October, 2009

Vol. 17: September, 2009

Vol. 16: August, 2009

Vol. 15: July, 2009

Vol. 13: June, 2009

Vol. 12: May, 2009

Vol. 11: April, 2009

Vol. 10: March, 2009

Vol. 9: February, 2009

Vol. 8: January, 2009

Vol. 7: December, 2008

Vol. 6: November, 2008

Vol. 5: October, 2008

Vol. 4: September, 2008

Vol. 3: August, 2008

Vol. 2:  July 1, 2008

Vol. 1:  June 1, 2008

 

 


Home | About Elaine | About the Book | Mission | ChemoTalk.com | Chemotalk Newsletter | Media Room |
Chemo Coaching | Speaking Engagements | Blog | Links | Contact